CureVac N.V. (CVAC)

CureVac is a pioneering biotech company focused on mRNA drugs for oncology and vaccines. In biotech, value derives from research quality, patent strength, and clinical success probability, not current revenues. CVAC boasts over 25 years of research and nearly 1,000 mRNA patents, highlighting its intellectual property strength.

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all shares of CureVac, uniting two highly complementary German companies to bring transformative mRNA-based treatments to patients globally Entered into agreements to resolve and dismiss all pending patent litigation in the U.S. with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines and to set a framework for resolving related ongoing patent disputes outside the U.S. upon closing of BioNTech's acquisition of CureVac Received Clinical Trial Application (CTA) clearance from the European Medicines Agency (EMA) for CVHNLC, a proprietary off-the-shelf cancer immunotherapy candidate targeting squamous non-small cell lung cancer (sqNSCLC) CVGBM glioblastomadata from Part B of Phase 1 remain on track for H2 2025 Strong cash and cash equivalents position of €392.7 million as of June 30, 2025; expected cash runway into 2028 TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / August 15, 2025 / CureVac N.V. (Nasdaq:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced financial results for the second quarter and first half of 2025 and provided a business update.

GSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following a patent settlement involving BioNTech and Pfizer over messenger ribonucleic acid (mRNA) vaccine technology. The deal will also see GSK collect a 1% royalty on United States sales of Pfizer and BioNTech's influenza, COVID-19, and related combination mRNA vaccines from the start of 2025.

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.

TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of the Company's Annual General Meeting.

CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating CureVac N.V. (NASDAQ:  CVAC ) related to its sale to BioNTech SE. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. Is it a fair deal?

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

U.S. equities were mixed and little changed at midday as another key measure of inflation, the Producer Price Index (PPI), came in lower than expected. The S&P 500 and Nasdaq advanced, while the Dow Jones Industrial Average was lower.

Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that  BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.

BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.

BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, each share of CureVac will be exchanged for about $5.46 worth of BioNTech American Depositary Shares (ADSs), representing a premium of around 55% over CureVac's recent trading price.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. Halper Sadeh encourages CureVac shareholders to click here to learn more a.

CureVac stock soared 29% $5.26 in premarket trading immediately following the news.

German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.

U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial Application filed in Europe with decision expected in Q2 2025 Glioblastoma study fully enrolled with Part B of Phase 1 CVGBM trial completing enrolment in Q1 2025; go/no-go decision on moving to Phase 2 planned for H2 2025 First urinary tract infection vaccine moving forward with U.S. IND filing planned for H2 2025 Core mRNA patents upheld as European Patent Office confirmed validity of two key patents in amended form; infringement hearing against BioNTech/Pfizer before the Regional Court Düsseldorf set for July 1, 2025 Strong cash and cash equivalents position of €438.3 million as of March 31, 2025; reaffirming expected cash runway into 2028 TÜBINGEN, GERMANY and BOSTON, MA / ACCESS Newswire / May 20, 2025 / CureVac N.V. (Nasdaq:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced financial results for the first quarter of 2025 and provided a business update.